Catalyst Event

Biogen Inc (BIIB) · Other

From KEDI Tesla Fixed Tech100 Index (KTSLT100)

6/4/2026, 12:00:00 AM

OtherSentiment: Positive

The U.S. FDA granted Breakthrough Therapy Designation to salanersen, an investigational therapy for spinal muscular atrophy (SMA), to expedite its development and review. This designation is estimated to have a price impact of over 10% due to the significantly accelerated path to market for a high-potential therapy.

Korean Translation

미국 FDA에서 척수성 근위축증(SMA) 치료 후보물질 살라너센(salanersen)을 혁신치료제로 지정함. 개발 및 검토 가속화에 따른 시장 출시 단축으로 10% 이상의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline